Archive for the 'Testosterone' Category

Nov 11 2014

UTMB study shows testosterone therapy does not increase heart attack risk

Published by under Testosterone

PUBLIC RELEASE DATE: 2-Jul-2014

Contact: Donna Ramirez

 

UTMB study shows testosterone therapy does not increase heart attack risk

Testosterone prescriptions for older men in the United States have increased more than three-fold over the past decade. Recent studies linking testosterone use with increased risk of heart attack and stroke have caused widespread concern among patients and their families. A new U.S.-based study of more than 25,000 older men shows that testosterone therapy does not increase men’s risk for heart attack.

The study, conducted by researchers at the University of Texas Medical Branch at Galveston, examined 25,420 Medicare beneficiaries 66 years or older treated with testosterone for up to eight years. It appears in the July 2 issue of theAnnals of Pharmacotherapy.

“Our investigation was motivated by a growing concern, in the U.S. and internationally, that testosterone therapy increases men’s risk for cardiovascular disease, specifically heart attack and stroke,” said Jacques Baillargeon, UTMB associate professor of epidemiology in the Department of Preventive Medicine and Community Health and lead author of the study. “This concern has increased in the last few years based on the results of a clinical trial and two observational studies,” he said. “It is important to note, however, that there is a large body of evidence that is consistent with our finding of no increased risk of heart attack associated with testosterone use.”

In recent years, the testosterone therapy market has grown to $1.6 billion annually as men seek to supplement low testosterone counts with products that may increase muscle tone and sex drive. Previous safety investigations presented conflicting findings. A few of these studies suggest testosterone is linked with increased risk of heart attack, although some critics have questioned the quality of these data. Doctors, researchers and government agencies all agree that more research into this issue is necessary.

The Food and Drug Administration decided June 20 to expand labeling on testosterone products to include a general warning about the risk of blood clots in veins. The FDA and European Medicines Agency are also further examining the safety of these products. This newest FDA warning comes shortly after the announcement that several testosterone treatment manufacturers, including Abbott Laboratories, AbbVie Inc., Eli Lilly and Company, Pfizer and Actavis, are facing a consolidated multidistrict litigation in Federal Court based on claims that they hid the risks of using testosterone treatments.

This new UTMB study evaluated enrollment and claims Medicare data for a clinically and socioeconomically diverse national sample treated with testosterone from 1997-2005. Men of the same age, race, Medicaid eligibility, and health status who did not receive testosterone therapy were used as a control group for comparison.

The analyses show that testosterone therapy was not associated with an increased risk of heart attack. Further, testosterone users with a higher probability of cardiovascular problems had a lower rate of heart attacks in comparison to equivalent patients who did not receive testosterone therapy.

“This is a rigorous analysis of a large number of patients,” said Baillargeon. “Our findings did not show an increased risk of heart attack associated with testosterone use in older men,” he said. “However, large–scale, randomized clinical trials will provide more definitive evidence regarding these risks in the coming years.”

###

Additional authors for this paper include Randall Urban, Yong-Fang Kuo, Kenneth Ottenbacher, Mukaila Raji, Fei Du, Yu-li Lin and James Goodwin. The National Institutes of Health and the Agency for Healthcare Research and Quality supported this research.

The University of Texas Medical Branch
Office of Marketing and Communications
301 University Boulevard, Suite 3.518
Galveston, Texas 77555-0144

ABOUT UTMB HEALTH: Texas’ first academic health center opened its doors in 1891 and today comprises four health sciences schools, three institutes for advanced study, a research enterprise that includes one of only two national laboratories dedicated to the safe study of infectious threats to human health, and a health system offering a full range of primary and specialized medical services throughout Galveston County and the Texas Gulf Coast region. UTMB Health is a component of the University of Texas System and a member of the Texas Medical Center.

No responses yet

Sep 23 2010

Testosterone for Women?

Johns Hopkins Health Alert
Testosterone for Women

Comments (0)

If a woman’s sexual problems are biological rather than psychological, testosterone therapy may help.

Men may have grabbed the sexual spotlight with Viagra (sildenafil citrate) and erectile dysfunction (ED), but women are equally prone to have concerns about their sex lives. While there may not be a woman’s equivalent to Viagra, if you are concerned about sex, take comfort in knowing that you are not alone. Upwards of 43% of women report some degree of dissatisfaction with their sexual health — and help is available.

Experts believe that in women, the physical aspect of desire is governed by the male sex hormone, testosterone. Men and women produce both sex hormones, though not in equal amounts. By menopause, a woman produces 50% as much testosterone as she did in her 20s. The loss of testosterone occurs gradually over many years and is unrelated to menopause; however, its impact on desire becomes most evident around menopause, when estrogen production drops off completely. Many experts believe that boosting women’s testosterone levels will improve their libido.

The International Journal of Impotence Research recently reviewed 12 trials comparing testosterone replacement with placebo iACn postmenopausal women taking estrogen and concluded that testosterone therapy stimulates sexual desire and improves sexual satisfaction. The North American Menopause Society (NAMS) has come to similar conclusions and recommends testosterone to treat hypoactive sexual desire disorder (HSDD).

Currently, though, the only testosterone product approved by the FDA for women is Estratest, a combination of estrogen and methyltestosterone (a type of testosterone that can be taken orally). It is approved only to relieve hot flashes. Still, many doctors prescribe the treatment “off-label” — outside of its FDA-approved use — for low desire. Testosterone products approved for men also are sometimes prescribed off-label for women. Less commonly, doctors may use testosterone injections.

There are some safety concerns with long-term testosterone use. A large epidemiological study of postmenopausal women published in the Archives of Internal Medicine reported an association between an increased risk of invasive breast cancer and the use of testosterone and estrogen. NAMS recommends women use testosterone along with estrogen, as it is used in most clinical trials, but that they use it for no more than six months.

Despite these concerns, Leonard DeRogatis, Ph.D., Director of The Center For Sexual Medicine at Sheppard Pratt and a Hopkins faculty member says, “It is highly unlikely that testosterone contributes to breast cancer.” The biggest problem with transdermal (through the skin) versions of testosterone is the potential for facial hair growth and transient acne. In severe instances methyltestosterone can cause liver toxicity, but these effects can be avoided by careful monitoring. “The testosterone patch is probably the most effective delivery system; however, it is not yet available in the United States,” says Dr. DeRogatis.

Although Dr. DeRogatis believes that women will someday benefit more fully from testosterone, he says they should expect to see effective nonhormonal therapies for HSDD in the future: “Some are in the making and development is likely to be pushed along as a result of women beginning to demand more options to improve their sex life.”

Taken from the March 2007 issue of the Johns Hopkins Medical Letter: Health After 50.

No responses yet

Jun 13 2008

Anabolic Hormone Depletion is Common in Men with Chronic Heart Failure

In a study involving 208 men with chronic heart failure (median age: 63 years) and 366 healthy controls, anabolic hormone depletion was found to be quite prevalent among men with chronic heart failure, and was found to be associated with poor prognostic consequences. Immunoassays were used to measure levels of various hormones in subjects. Results found that men of all ages with chronic heart failure were found to have deficiencies in DHEAS, circulating total testosterone (TT), estimated free testosterone (eFT), and insulin-like growth factor-1 (IGF-1). Furthermore, DHEAS, TT, and eFT were found to be inversely associated to New York Heart Association class. After adjusting for established prognostic factors, all four hormones were found to be prognostic markers as well. A positive association was found between DHEAS and left ventricular ejection fraction. Men with chronic heart failure but normal anabolic hormone levels had the best 3-year survival rates compared to those having deficiencies in one, two, or all three anabolic endocrine axes (74%, 55%, and 27%, respectively). These results suggest that men with chronic heart failure who have a deficiency in more than one anabolic hormone may have an increased risk of mortality.

Reference: “Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival,” Jankowska EA, Biel B, et al, Circulation, 2006; 114(17): 1829-37. (Address: Cardiology Department, Military Hospital, ul. Weigla 5, 50-981 Wroclaw, Poland. E-mail: Ewa.Jankowska@antro.pan.wroc.pl ).

No responses yet

Jun 10 2008

Testosterone Supplementation Decreases Metabolic Syndrome and Improves Sexual Function

Reports on hormones findings from F. Saad and co-researchers

“Administration of testosterone cypionate over 12 months to men with sexual dysfunction and signs of the metabolic syndrome, restored their plasma testosterone (T) levels to the mid-range of reference values. This had a beneficial effect on their sexual functioning as evidenced by an improvement of their scores on the International Index of Erectile Function,” researchers in Berlin, Germany report (see also Hormones).
“The scores on the Aging Male Symptoms score, AMS, were also improved. Most impressive were the improvements in the parameters of the metabolic syndrome; they all improved and appeared largely correlated (i.e., decline in waist circumference with declines of plasma cholesterol and LDL and increase in plasma HDL). Sex hormone binding globulin, SHBG, may be considered as an indicator of the severity of the metabolic syndrome; levels of SHBG initially fell, probably as a result of rising plasma T levels. But over the last six months of the observation period when plasma T rose further, there was a significant increase in plasma SHBG which may be interpreted to indicate an improvement of the metabolic syndrome. Blood pressure improved slightly but significantly. in this cohort of elderly men (54-76 years; median 64 years) there were no safety concerns over a one year period of T administration. Prostate specific antigen, PSA, levels remained stable; the International Prostate Symptoms Score, IPSS, improved slightly. Liver functions and plasma glucose remained stable,” wrote F. Saad and colleagues.

The researchers concluded: “Hemoglogin and hematocrit values increased but remained within reference values.”

Yours in health,

Griffin Medical Group

www.griffinmedical.com

No responses yet

Mar 18 2008

Grumpy Old Men: Maybe It’s A Question of Testosterone

February 26, 2008;

They’re bullish on testosterone here at the 6th Annual World Congress on the Aging Male.

Physicians and researchers from around the world gathered to review the latest findings on what low levels of the male hormone means for men, how replacing it might help and why it hasn’t caught on broadly.

“If we had a drug that could restore sexual function in men, make them stronger, build their bones, reduce fat and get rid of the blues, you’d say, ‘Oh my God, why doesn’t everybody know about it?’ ” says Abraham Morgentaler, a urologist at Harvard Medical School and director of the Men’s Health Boston clinic. “There is a drug like that — but the public associates testosterone with cheating and illicit behavior and the fact that 40 years ago, it was thought to give people prostate cancer.” Continue Reading »

One response so far

Dec 13 2006

Testosterone Replacement Therapy Appears Safe For Prostate

Source: JAMA and Archives Journals
Date: November 21, 2006
More on: Prostate Health, Men’s Health, Prostate Cancer, Urology, Diseases and Conditions, Erectile Dysfunction
Testosterone Replacement Therapy Appears Safe For Prostate
Preliminary research suggests that testosterone replacement therapy for men with low testosterone levels appears to have little effect on the prostate gland, contrary to some reports that this therapy may be harmful, according to a study in the November 15 issue of JAMA, a theme issue on men’s health. Leonard S. Marks, M.D., of the Urological Sciences Research Foundation and University of California, Los Angeles, presented the findings of the study today at a JAMA media briefing on men’s health in New York. Continue Reading »

No responses yet

Dec 12 2006

Bio-Identical Hormone Replacement (BHRT) Revives Youthful Energy and Vitality While Improving Quality of Life

Griffin Medical Group – Center for Anti-Aging and Aesthetics
Alvin M. Yee, M.D.

The old way of thinking was that humans age, and have naturally declining hormones as a result of aging. However, there are thousands of physicians and other medical professionals who are rethinking their belief of the old aging model. The formation and rapid growth of the American Academy of Anti-Aging Medicine (A4M) since 1993 is proof of this emerging trend. The latest in medical research now indicates that the degenerative process known as aging occurs precisely because of our declining hormones. With bio-identical hormone replacement therapy (BHRT), many studies have shown that the effects of aging can be greatly delayed, prevented or even reversed via supplementation of bio-identical hormones, by raising your hormones back to youthful levels. Continue Reading »

No responses yet

Dec 12 2006

What Men Don’t Know About Their Health and Aging Can Hurt Them– National Survey Finds That Most American Men Over the Age of 39 Fail to Attribute ‘Aging’ Symptoms to Low Testosterone, a Treatable Condition

PR Newswire 04-18-06
WASHINGTON, April 18, 2006 /PRNewswire via COMTEX/ —

A national survey released today indicates that one third of American men over the age of 39 report experiencing two or more symptoms of low testosterone (Low T), a condition that affects four to five million American males, marked by decreased energy, low libido, reduced muscle strength, increased body fat, weaker bones, and mood swings. The survey of 522 men over age 39, which was commissioned by the Alliance for Aging Research and conducted by Harris Interactive, shows that of those men experiencing two or more symptoms, 95 percent say their doctors did not mention Low T as a possible cause, even though it is known that the condition can be diagnosed with a simple blood test. Given the high percentage of men experiencing symptoms associated with Low T, general lack of awareness and reported willingness to treat those symptoms, the Alliance for Aging Research, a nonprofit, independent organization promoting public health education, announced today the launch of the Men’s Health and Aging in America campaign. The campaign aims to raise awareness of Low T, encourage testing for Low T, and educate the public about treatment options. Continue Reading »

No responses yet

Dec 10 2006

Human Chorionic Gonadrotropin

HCG is provided as a glycoprotein powder to be diluted with water, and acts in the body like luteinizing hormone (LH), stimulating the testes to produce testosterone even when natural LH is not present or is deficient. It therefore is useful for maintaining testosterone production and testicle size during testosterone replacement therapy(TRT). Use of this drug in the taper is rather counterproductive, since the resulting increased testosterone production is itself inhibitory to the hypothalamus and pituitary, delaying recovery. Thus, if this drug is used, it is preferably used during the (TRT) cycle itself. A daily amount of 500 IU is generally sufficient, and in my opinion usage should not exceed 1000 IU per day.

Daily administration is superior to less frequent administration.

Doses over 1000 IU are noted for their tendency to cause or aggravate gynecomastia, and also act to desensitize the testicles to LH.

HCG may be injected intramuscularly, subcutaneously, or in a shallow injection about 1/4″ deep with the needle going straight in. A 29 gauge insulin needle is recommended. Injection speed should be slow.

Some HCG products are diluted 5000 or even 10,000 IU per mL, while others are diluted 1000 IU per mL. So far as I know there is no need to make the preparation so dilute. Once mixed, the preparation should be refrigerated and used within a few weeks. The substance is also somewhat temperature sensitive before mixing and should not be exposed to excessive heat.

HCG can also useful for returning testosterone to normal levels should levels be low post (TRT), or, with care, to increase levels from normal to high normal. Titration of the dose, by measuring Testosterone levels and then adjusting the HCG dose accordingly, is recommended for long term use. An aromotase inhibitor like anastrozole is recommended to prevent any conversion to estrogen.

No responses yet

Dec 07 2006

How Low Testosterone Negatively Affects Quality of Life

WebMD Medical News
Reviewed By Louise Chang, MD
on Wednesday, July 05, 2006
July 5, 2006 — Older men with common health problems such as obesityobesity, diabetesdiabetes, and high blood pressure may be twice as likely as other men their age to have low testosterone levels, according to a new study. Continue Reading »

No responses yet

Dec 04 2006

Studies Indicating That Testosterone Does Not Cause Prostate Cancer

Study 1
“This nested case-control study was based on the cohort of men who donated blood to the Janus serum bank at Oslo University Hospital between 1973 and 1994. Cancer incidence was ascertained through linkage with the Norwegian Cancer Registry. The study included sera from 59 men who developed prostate cancer subsequent to blood donation and 180 men who were Continue Reading »

No responses yet

Dec 01 2006

Improve Your Sex Life And Protect Against Heart Attack

Did you know that testosterone deficiency predisposes men to heart disease, depression and a host of other ailments associated with normal aging? Continue Reading »

One response so far

Dec 01 2006

MALE HORMONES AND AGING

As men age past age 40, hormonal changes occur that perceptibly inhibit physical, sexual, and cognitive function. The outward appearance of a typical middle-aged male shows increased abdominal fat and shrinkage of muscle mass, a hallmark effect of hormone imbalance (94-97, 271).1 Loss of a feeling of well-being, sometimes manifesting as depression, is a common Continue Reading »

No responses yet

Supply of hospital pharmacies operating externally due to cost savings will continue to grow all over the next years. Even today, 90% of all pharmacies pribolnichnyh organized in cooperation provisioning This shows that the Canadian pharmacy online has become not take seriously the business partner compared with the pharmaceutical industry. However, the development of recent years shows that the industry sees its price registration stronger with the number of sales, thus strengthening the competitiveness of supplying hospital pharmacies in the long term due to more efficient logistics and a lot of sales.